{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122810","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.114996+00:00","generated_at":"2026-05-30T03:36:41.798938+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Intellia Q3 net loss $135.7M; cash $944.7M; FDA clears Phase 3 for nex-z polyneuropathy","bullets":["Net loss $135.7M vs $122.2M YoY; cash $944.7M (down from $1.0B at Dec 31).","FDA IND clearance for MAGNITUDE-2 Phase 3 trial of nex-z for ATTRv polyneuropathy; enrollment on track by year-end.","MAGNITUDE Phase 3 (ATTR-CM) enrollment tracking ahead; HAELO Phase 3 (HAE) actively screening.","Positive Phase 2 data for NTLA-2002: 8/11 patients attack-free after single 50mg dose; no serious AEs.","On track to dose first patient in NTLA-3001 Phase 1/2 for AATD by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122810","json":"https://secwatch.observer/filing/0000950170-24-122810.json","markdown":"https://secwatch.observer/filing/0000950170-24-122810.md","text":"https://secwatch.observer/filing/0000950170-24-122810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024122810/0000950170-24-122810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024122810/ntla-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:36:41.798938+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}